Maofu Liao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Maofu Liao has a total of 247 co-authors. Here are the top co-authors by number of shared publications:
Chen Xu
Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA 01605, USA; Cryo-EM Core Facility, University of Massachusetts Medical School, Worcester, MA 01605, USA
10 shared publicationsKangkang Song
Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA 01605, USA; Cryo-EM Core Facility, University of Massachusetts Medical School, Worcester, MA 01605, USA
6 shared publications- Robert V. Farese
Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, USA
6 shared publications - Tobias Christian Walther
Cell Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
6 shared publications Benjamin J. Orlando
Department of Cell Biology, Harvard Medical School, Boston, USA
5 shared publicationsKun Wang
Department of Cell Biology, Harvard Medical School, Boston, USA
5 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Springer Nature in npj Antimicrobials and Resistance
Non‑nucleoside inhibitors of SARS‑CoV‑2 RdRp identified by high‑throughput screening and an approach to their mechanism of action by comparative studies
The RNA-dependent RNA polymerase (RdRp) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a pivotal antiviral target due to its essential role in viral replication and high conservation. Non-nucleoside analog inhibitors (NNIs) are a promising class of antiviral compounds that target SARS-CoV-2 RdRp, potentially circumventing resistance profiles associated with nucleoside analogues. Although multiple NNIs against SARS-CoV-2 RdRp have been reported, the knowledge regarding the modes of action remains fragmented, and the lack of a standardized cell-free assay has hindered cross-comparison of various NNIs. Notably, whether clinically approved drugs or the NNIs targeting hepatitis C virus (HCV) RdRp (NS5B) can be used to inhibit SARS-CoV-2 RdRp remains largely unexplored, and the chemical and mechanistic diversity of the NNIs are poorly defined. Here, we conducted a high-throughput screening of an FDA-approved drug library using a fluorescence-based RNA polymerase assay to identify novel NNIs targeting SARS-CoV-2 RdRp. Twenty-nine primary hits, along with sixteen previously reported SARS-CoV-2 NNIs and ten HCV RdRp NNIs, were systematically evaluated using a gel-based RdRp inhibition assay, resulting in seventeen positive compounds which include five novel inhibitors (verteporfin, benzbromarone, epigallocatechin gallate, mitoxantrone, and trifarotene) and two NNIs targeting HCV NS5B (JTK-109 and BILB-1941). Parallel dose-response analysis enabled direct efficacy comparison of the NNIs, showing suramin, C646, and baicalein as the most potent inhibitors. Gel mobility shift assay further revealed varied kinetics of the NNIs in disrupting the RdRp-RNA interaction, reflecting their diverse inhibitory mechanisms. Together, our findings expand the repertoire of NNIs against SARS-CoV-2 RdRp, establish a unified framework for comparative evaluation of RdRp inhibitors, and provide insights into the differential impacts of the NNIs on RdRp-RNA complex formation, thereby supporting future development of allosteric antiviral therapeutics.
- 15 September 2026
- Published by Springer Nature in npj Antimicrobials and Resistance
Open AccessNon‑nucleoside inhibitors of SARS‑CoV‑2 RdRp identified by high‑throughput screening and an approach to their mechanism of action by comparative studies
The RNA-dependent RNA polymerase (RdRp) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a pivotal antiviral target due to its essential role in viral replication and high conservation. Non-nucleoside analog inhibitors (NNIs) are a promising class of antiviral compounds that target SARS-CoV-2 RdRp, potentially circumventing resistance profiles associated with nucleoside analogues. Although multiple NNIs against SARS-CoV-2 RdRp have been reported, the knowledge regarding the modes of action remains fragmented, and the lack of a standardized cell-free assay has hindered cross-comparison of various NNIs. Notably, whether clinically approved drugs or the NNIs targeting hepatitis C virus (HCV) RdRp (NS5B) can be used to inhibit SARS-CoV-2 RdRp remains largely unexplored, and the chemical and mechanistic diversity of the NNIs are poorly defined. Here, we conducted a high-throughput screening of an FDA-approved drug library using a fluorescence-based RNA polymerase assay to identify novel NNIs targeting SARS-CoV-2 RdRp. Twenty-nine primary hits, along with sixteen previously reported SARS-CoV-2 NNIs and ten HCV RdRp NNIs, were systematically evaluated using a gel-based RdRp inhibition assay, resulting in seventeen positive compounds which include five novel inhibitors (verteporfin, benzbromarone, epigallocatechin gallate, mitoxantrone, and trifarotene) and two NNIs targeting HCV NS5B (JTK-109 and BILB-1941). Parallel dose-response analysis enabled direct efficacy comparison of the NNIs, showing suramin, C646, and baicalein as the most potent inhibitors. Gel mobility shift assay further revealed varied kinetics of the NNIs in disrupting the RdRp-RNA interaction, reflecting their diverse inhibitory mechanisms. Together, our findings expand the repertoire of NNIs against SARS-CoV-2 RdRp, establish a unified framework for comparative evaluation of RdRp inhibitors, and provide insights into the differential impacts of the NNIs on RdRp-RNA complex formation, thereby supporting future development of allosteric antiviral therapeutics.
- Open Access
- 6 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Structure and druggable conformation of the homodimeric lipoprotein transporter of Acinetobacter baumannii
The growing crisis of antimicrobial resistance demands urgent need for antibiotics with alternative targets and modes of action (MOAs). Lipoproteins play crucial roles in bacterial survival and immunoregulation. The lipoprotein transporter, known as LolCDE or LolDF, has recently emerged as an effective target for selectively killing pathogenic bacteria such as Acinetobacter baumannii while sparing gut microbiota. While the heterodimeric LolCDE in Escherichia coli has been extensively studied, the druggable pocket and structural dynamics of the distinct homodimeric LolDF that exists in many critical pathogens are poorly understood. Such a knowledge gap limits our ability to exploit the Lol system to develop drugs with desired spectra of antibacterial activity. Here we determine the cryo-EM structures of homodimeric LolDF of A. baumannii in nucleotide-free apo-closed, vanadate-trapped fully closed, and inhibitor-bound open conformations, revealing the distinct structural features and conformational cycle of LolDF. Further cryo-EM, biochemical and functional analyses uncover the MOA of abaucin, a recently identified LolDF-targeting compound, demonstrating how multiple abaucin molecules open LolDF in a stepwise manner to establish an induced-fit pocket. Together, our results advance the understanding of LolDF function and inhibition, and provide the cryptic druggable conformation and specific inhibitor-bound pocket for structure-based drug discovery to target the dynamic lipoprotein transporter in A. baumannii.
- 6 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessStructure and druggable conformation of the homodimeric lipoprotein transporter of Acinetobacter baumannii
The growing crisis of antimicrobial resistance demands urgent need for antibiotics with alternative targets and modes of action (MOAs). Lipoproteins play crucial roles in bacterial survival and immunoregulation. The lipoprotein transporter, known as LolCDE or LolDF, has recently emerged as an effective target for selectively killing pathogenic bacteria such as Acinetobacter baumannii while sparing gut microbiota. While the heterodimeric LolCDE in Escherichia coli has been extensively studied, the druggable pocket and structural dynamics of the distinct homodimeric LolDF that exists in many critical pathogens are poorly understood. Such a knowledge gap limits our ability to exploit the Lol system to develop drugs with desired spectra of antibacterial activity. Here we determine the cryo-EM structures of homodimeric LolDF of A. baumannii in nucleotide-free apo-closed, vanadate-trapped fully closed, and inhibitor-bound open conformations, revealing the distinct structural features and conformational cycle of LolDF. Further cryo-EM, biochemical and functional analyses uncover the MOA of abaucin, a recently identified LolDF-targeting compound, demonstrating how multiple abaucin molecules open LolDF in a stepwise manner to establish an induced-fit pocket. Together, our results advance the understanding of LolDF function and inhibition, and provide the cryptic druggable conformation and specific inhibitor-bound pocket for structure-based drug discovery to target the dynamic lipoprotein transporter in A. baumannii.
- Open Access
- 4 April 2026
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 18 (1)
Constructing and characterizing trillion-scale combinatorial chemical library
The scale of screening within ultra-large chemical spaces plays a pivotal role in contemporary drug discovery, particularly during the initial stages of hi
- 4 April 2026
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 18 (1)
Open AccessConstructing and characterizing trillion-scale combinatorial chemical library
The scale of screening within ultra-large chemical spaces plays a pivotal role in contemporary drug discovery, particularly during the initial stages of hi
- Open Access
Characterisation of plasmablast-derived HBsAg-specific antibody and its structural basis for binding to native HBsAg dimer
Background: Plasmablast-derived HBV surface antigen (HBsAg)-specific monoclonal antibody (mAb) and structural basis for binding to native HBsAg are poorly known. Objective: We aimed to identify plasmablast-derived HBsAg-specific mAbs, evaluate their antiviral activities and resolve their structure for binding to native HBsAg. Design: A previously vaccinated volunteer was enrolled in this study, who was boosted with a dose of recombinant hepatitis B vaccine and donated the blood sample. Activated plasmablasts were sorted from fresh peripheral blood mononuclear cells and mAbs were expressed. Their gene features, cross-genotypic binding activities and antiviral functions in vitro and in vivo were comprehensively analysed. The cryo-electron microscopy (cryo-EM) was used to determine the structure of representative mAb bound to the native HBsAg. Results: In this study, we cloned a series of HBsAg-specific mAbs directly from clonally expanded plasmablasts from a vaccinated individual. Most of the mAbs displayed cross-reactivities of binding to different genotype HBsAg proteins and antiviral functions such as neutralisation and antibody-dependent cellular phagocytosis. These human anti-HBsAg mAbs, especially SY-4-class and SY-23-class, could be good candidates for antibody drugs. The cryo-EM structure of SY-23 bound to the dimeric HBsAg was determined, revealing its binding mechanism and unprecedented structural detail of the major antigenic loop (AGL) of HBsAg. Conclusion: Overall, our work has uncovered the diverse gene features and varied anti-HBV activities of plasmablast-derived mAbs, providing a series of antibody drug candidates and the long-sought-after atomic model of AGL has paved the way for a wholistic characterisation of the AGL’s dynamic conformation during HBV infection and immune response.
Open AccessCharacterisation of plasmablast-derived HBsAg-specific antibody and its structural basis for binding to native HBsAg dimer
Background: Plasmablast-derived HBV surface antigen (HBsAg)-specific monoclonal antibody (mAb) and structural basis for binding to native HBsAg are poorly known. Objective: We aimed to identify plasmablast-derived HBsAg-specific mAbs, evaluate their antiviral activities and resolve their structure for binding to native HBsAg. Design: A previously vaccinated volunteer was enrolled in this study, who was boosted with a dose of recombinant hepatitis B vaccine and donated the blood sample. Activated plasmablasts were sorted from fresh peripheral blood mononuclear cells and mAbs were expressed. Their gene features, cross-genotypic binding activities and antiviral functions in vitro and in vivo were comprehensively analysed. The cryo-electron microscopy (cryo-EM) was used to determine the structure of representative mAb bound to the native HBsAg. Results: In this study, we cloned a series of HBsAg-specific mAbs directly from clonally expanded plasmablasts from a vaccinated individual. Most of the mAbs displayed cross-reactivities of binding to different genotype HBsAg proteins and antiviral functions such as neutralisation and antibody-dependent cellular phagocytosis. These human anti-HBsAg mAbs, especially SY-4-class and SY-23-class, could be good candidates for antibody drugs. The cryo-EM structure of SY-23 bound to the dimeric HBsAg was determined, revealing its binding mechanism and unprecedented structural detail of the major antigenic loop (AGL) of HBsAg. Conclusion: Overall, our work has uncovered the diverse gene features and varied anti-HBV activities of plasmablast-derived mAbs, providing a series of antibody drug candidates and the long-sought-after atomic model of AGL has paved the way for a wholistic characterisation of the AGL’s dynamic conformation during HBV infection and immune response.
- Open Access
- 1 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-8
Lysosome-mediated aggregation of galactose-deficient IgA1 with transferrin receptor 1 links to IgA nephropathy
Purpose Although endonasal endoscopic surgery (EES) is widely used to treat symptomatic Rathke’s cleft cysts (RCCs), the optimal surgical strategy remains unclear. We previously proposed that the anatomical relationship between RCCs and the anterior pituitary lobe may predict recurrence. This study aimed to evaluate clinical characteristics and long-term outcomes based on anatomical classification and to assess the impact of surgical method (marsupialization vs. reconstruction) within each subtype. Methods We retrospectively analyzed 40 patients who underwent EES for symptomatic RCCs between 2008 and 2024. RCCs were classified into four types based on displacement: type 1 (anterior-superior), type 2 (anterior-inferior), type 3 (posterior-superior), and type 4 (posterior-inferior). Clinical, imaging, and surgical outcomes were compared across subtypes. Results he mean follow-up duration was 112 ± 53.2 months. Recurrence occurred in 16 patients (40.0%), and 6 (15.0%) patients required reoperation. Type 2 was independently associated with a higher recurrence rate (p = 0.019), more frequent preoperative visual disturbances (p = 0.0059), and lower T1-weighted signal intensity (p = 0.027). There was no significant difference in the recurrence rate between the surgical methods within each subtype. Conclusion The anterior-inferior subtype is more likely to recur regardless of the surgical method. The identification of high-risk subtypes may support the use of tailored strategies, including drainage-preserving techniques, to improve long-term outcomes.
- 1 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-8
Open AccessLysosome-mediated aggregation of galactose-deficient IgA1 with transferrin receptor 1 links to IgA nephropathy
Purpose Although endonasal endoscopic surgery (EES) is widely used to treat symptomatic Rathke’s cleft cysts (RCCs), the optimal surgical strategy remains unclear. We previously proposed that the anatomical relationship between RCCs and the anterior pituitary lobe may predict recurrence. This study aimed to evaluate clinical characteristics and long-term outcomes based on anatomical classification and to assess the impact of surgical method (marsupialization vs. reconstruction) within each subtype. Methods We retrospectively analyzed 40 patients who underwent EES for symptomatic RCCs between 2008 and 2024. RCCs were classified into four types based on displacement: type 1 (anterior-superior), type 2 (anterior-inferior), type 3 (posterior-superior), and type 4 (posterior-inferior). Clinical, imaging, and surgical outcomes were compared across subtypes. Results he mean follow-up duration was 112 ± 53.2 months. Recurrence occurred in 16 patients (40.0%), and 6 (15.0%) patients required reoperation. Type 2 was independently associated with a higher recurrence rate (p = 0.019), more frequent preoperative visual disturbances (p = 0.0059), and lower T1-weighted signal intensity (p = 0.027). There was no significant difference in the recurrence rate between the surgical methods within each subtype. Conclusion The anterior-inferior subtype is more likely to recur regardless of the surgical method. The identification of high-risk subtypes may support the use of tailored strategies, including drainage-preserving techniques, to improve long-term outcomes.
- Open Access
- 13 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (24) , eadv9721
Conformational cycle and small-molecule inhibition mechanism of a plant ABCB transporter in lipid membranes
In plants, ATP-binding cassette (ABC) transporters are crucial for nutrient uptake, phytohormone transport, and environmental response. It is of great interest to understand the mechanisms of these transporters and develop small-molecule modulators to regulate plant growth. Arabidopsis ABCB19 was recently shown to transport brassinosteroid, shaping hormone dynamics and plant architecture. However, the conformational cycle and inhibitor mechanism of ABCB transporters remain elusive. We reconstituted ABCB19 into lipid nanodiscs, where activity was drastically higher than in detergents, and determined its cryo–electron microscopy structures in substrate-free, substrate-bound, vanadate-trapped, and inhibitor-bound states. Inward-facing ABCB19 moved inward upon substrate binding and fully closed with vanadate trapping, unexpectedly temperature dependent. Two inhibitor molecules locked ABCB19 in the inward-facing conformation. Mutagenesis identified key residues for substrate and inhibitor binding, revealing differential contributions to transporter function and inhibition. These results deepen knowledge of plant ABCB transporters, laying a foundation for targeted manipulation to enhance plant resilience and productivity.
- 13 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (24) , eadv9721
Open AccessConformational cycle and small-molecule inhibition mechanism of a plant ABCB transporter in lipid membranes
In plants, ATP-binding cassette (ABC) transporters are crucial for nutrient uptake, phytohormone transport, and environmental response. It is of great interest to understand the mechanisms of these transporters and develop small-molecule modulators to regulate plant growth. Arabidopsis ABCB19 was recently shown to transport brassinosteroid, shaping hormone dynamics and plant architecture. However, the conformational cycle and inhibitor mechanism of ABCB transporters remain elusive. We reconstituted ABCB19 into lipid nanodiscs, where activity was drastically higher than in detergents, and determined its cryo–electron microscopy structures in substrate-free, substrate-bound, vanadate-trapped, and inhibitor-bound states. Inward-facing ABCB19 moved inward upon substrate binding and fully closed with vanadate trapping, unexpectedly temperature dependent. Two inhibitor molecules locked ABCB19 in the inward-facing conformation. Mutagenesis identified key residues for substrate and inhibitor binding, revealing differential contributions to transporter function and inhibition. These results deepen knowledge of plant ABCB transporters, laying a foundation for targeted manipulation to enhance plant resilience and productivity.
- Open Access
- 16 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-11
Cryo-EM of human P-glycoprotein reveals an intermediate occluded conformation during active drug transport
P-glycoprotein (Pgp) is an important human multidrug transporter that contributes to pharmacokinetics and multidrug resistance. Despite decades of study, the conformation transition cycle of Pgp undergoing active drug transport is not defined, thus the precise relevance of all available Pgp structures to uninterrupted multidrug transport remains unclear. Here, we use cryo-EM of membrane-embedded human Pgp under continuous turnover conditions to analyze the conformational ensembles of Pgp transporting distinct substrates. These results delineate multiple conformations including inward-facing and closed conformations, highlighting the occluded conformation as a critical intermediate state between transporter closure and substrate release. A combination of structural, functional, and computational studies reveals the transmembrane helices 4 and 10 undergoing drastic rearrangement to coordinate substrate binding, occlusion, and release, and identifies a peripheral site involved in substrate capture and Pgp inhibition. Together, our results provide a set of snapshots of Pgp undergoing continuous drug transport, unveiling the intricate interplay between transporter dynamics and drug movement, and shed light on the mechanism of polyspecificity.
- 16 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-11
Open AccessCryo-EM of human P-glycoprotein reveals an intermediate occluded conformation during active drug transport
P-glycoprotein (Pgp) is an important human multidrug transporter that contributes to pharmacokinetics and multidrug resistance. Despite decades of study, the conformation transition cycle of Pgp undergoing active drug transport is not defined, thus the precise relevance of all available Pgp structures to uninterrupted multidrug transport remains unclear. Here, we use cryo-EM of membrane-embedded human Pgp under continuous turnover conditions to analyze the conformational ensembles of Pgp transporting distinct substrates. These results delineate multiple conformations including inward-facing and closed conformations, highlighting the occluded conformation as a critical intermediate state between transporter closure and substrate release. A combination of structural, functional, and computational studies reveals the transmembrane helices 4 and 10 undergoing drastic rearrangement to coordinate substrate binding, occlusion, and release, and identifies a peripheral site involved in substrate capture and Pgp inhibition. Together, our results provide a set of snapshots of Pgp undergoing continuous drug transport, unveiling the intricate interplay between transporter dynamics and drug movement, and shed light on the mechanism of polyspecificity.
- Open Access
- 29 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (48) , eadn6037
The crystal and cryo-EM structures of PLCγ2 reveal dynamic interdomain recognitions in autoinhibition
Phospholipase C gamma 2 (PLCγ2) plays important roles in cell signaling downstream of various membrane receptors. PLCγ2 contains a multidomain inhibitory region critical for its regulation, while it has remained unclear how these domains contribute to PLCγ2 activity modulation. Here we determined three structures of human PLCγ2 in autoinhibited states, which reveal dynamic interactions at the autoinhibition interface, involving the conformational flexibility of the Src homology 3 (SH3) domain in the inhibitory region, and its previously unknown interaction with a carboxyl-terminal helical domain in the core region. We also determined a structure of PLCγ2 bound to the kinase domain of fibroblast growth factor receptor 1 (FGFR1), which demonstrates the recognition of FGFR1 by the nSH2 domain in the inhibitory region of PLCγ2. Our results provide structural insights into PLCγ2 regulation that will facilitate future mechanistic studies to understand the entire activation process.
- 29 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (48) , eadn6037
Open AccessThe crystal and cryo-EM structures of PLCγ2 reveal dynamic interdomain recognitions in autoinhibition
Phospholipase C gamma 2 (PLCγ2) plays important roles in cell signaling downstream of various membrane receptors. PLCγ2 contains a multidomain inhibitory region critical for its regulation, while it has remained unclear how these domains contribute to PLCγ2 activity modulation. Here we determined three structures of human PLCγ2 in autoinhibited states, which reveal dynamic interactions at the autoinhibition interface, involving the conformational flexibility of the Src homology 3 (SH3) domain in the inhibitory region, and its previously unknown interaction with a carboxyl-terminal helical domain in the core region. We also determined a structure of PLCγ2 bound to the kinase domain of fibroblast growth factor receptor 1 (FGFR1), which demonstrates the recognition of FGFR1 by the nSH2 domain in the inhibitory region of PLCγ2. Our results provide structural insights into PLCγ2 regulation that will facilitate future mechanistic studies to understand the entire activation process.
- Open Access
- 4 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Structures of the Mycobacterium tuberculosis efflux pump EfpA reveal the mechanisms of transport and inhibition
As the first identified multidrug efflux pump in Mycobacterium tuberculosis (Mtb), EfpA is an essential protein and promising drug target. However, the functional and inhibitory mechanisms of EfpA are poorly understood. Here we report cryo-EM structures of EfpA in outward-open conformation, either bound to three endogenous lipids or the inhibitor BRD-8000.3. Three lipids inside EfpA span from the inner leaflet to the outer leaflet of the membrane. BRD-8000.3 occupies one lipid site at the level of inner membrane leaflet, competitively inhibiting lipid binding. EfpA resembles the related lysophospholipid transporter MFSD2A in both overall structure and lipid binding sites and may function as a lipid flippase. Combining AlphaFold-predicted EfpA structure, which is inward-open, we propose a complete conformational transition cycle for EfpA. Together, our results provide a structural and mechanistic foundation to comprehend EfpA function and develop EfpA-targeting anti-TB drugs.
- 4 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Open AccessStructures of the Mycobacterium tuberculosis efflux pump EfpA reveal the mechanisms of transport and inhibition
As the first identified multidrug efflux pump in Mycobacterium tuberculosis (Mtb), EfpA is an essential protein and promising drug target. However, the functional and inhibitory mechanisms of EfpA are poorly understood. Here we report cryo-EM structures of EfpA in outward-open conformation, either bound to three endogenous lipids or the inhibitor BRD-8000.3. Three lipids inside EfpA span from the inner leaflet to the outer leaflet of the membrane. BRD-8000.3 occupies one lipid site at the level of inner membrane leaflet, competitively inhibiting lipid binding. EfpA resembles the related lysophospholipid transporter MFSD2A in both overall structure and lipid binding sites and may function as a lipid flippase. Combining AlphaFold-predicted EfpA structure, which is inward-open, we propose a complete conformational transition cycle for EfpA. Together, our results provide a structural and mechanistic foundation to comprehend EfpA function and develop EfpA-targeting anti-TB drugs.